Company intelligence / Profile preview

ZMI Pharma, Inc.

Carlsbad, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Commercial

Overview

ZMI Pharma manufactures and markets ZIMHI™, a high-concentration naloxone injection for emergency treatment of opioid overdoses. The product was acquired from DMK Pharmaceuticals in May 2024 via bankruptcy court sale. Manufacturing will resume at the new Carlsbad facility in October 2024. Current inventory remains available through exclusive distributor FFF Enterprises. No new clinical results reported; the focus is on commercial supply continuity.

Therapeutic areas: Neurology
Modalities: Small molecules (naloxone injection device)
Industry: Biotech

Drug pipeline

1 asset

naloxone

Commercial

Indications: Opioid overdose, Fentanyl poisoning

Partnerships

FFF Enterprises (exclusive U.S. distributor for ZIMHI™)

Beyond the preview

Go deeper on ZMI Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZMI Pharma, Inc..

Explore the full profile